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INTRODUCTION
Synchronous primary tumors of the female reproductive 
organs are relatively rare and it is observed most frequently 
in endometrial and ovarian cancers. It has been reported that 
primary cancers of the endometrium and ovary coexist in 
approximately 10% of all women with ovarian cancer and in 
5% of all women with endometrial cancer [1]. The underlying 
cause and pathogenesis remains unclear though some re-
searchers have postulated that embryologically similar tissues 
may develop synchronous neoplasms when there is simulta-
neous exposure to carcinogens or hormonal influences [2,3]. 
Most of the women present about a decade younger than the 
median ages of development of endometrial or ovarian can-
cer alone. 
The aim of our study is to look at the clinicopathological 
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Objective: Synchronous occurrence of endometrial and ovarian tumors is uncommon, and they affect less than 10% of women 
with endometrial or ovarian cancers. The aim of this study is to describe the epidemiological and clinical factors; and survival 
outcomes of women with these cancers.
Methods: This is a retrospective cohort study in a large tertiary institution in Singapore. The sample consists of women with 
endometrial and epithelial ovarian cancers followed up over a period of 10 years from 2000 to 2009. The epidemiological and 
clinical factors include age at diagnosis, histology types, grade and stage of disease.
Results: A total of 75 patients with synchronous ovarian and endometrial cancers were identified. However, only 46 patients met 
the inclusion criteria. The median follow-up was 74 months. The incidence rate for synchronous cancer is 8.7% of all epithelial 
ovarian cancers and 4.9% of all endometrial cancers diagnosed over this time frame. Mean age at diagnosis was 47.3 years old. 
The most common presenting symptom was abnormal uterine bleeding (36.9%) and 73.9% had endometrioid histology for 
both endometrial and ovarian cancers. The majority of the women (78%) presented were at early stages of 1 and 2. There were 
6 (13.6%) cases of recurrence and the 5 year cumulative survival rate was at 84%.
Conclusion: In our cohort, we found that majority of women afflicted with synchronous cancer of the endometrium and ovary 
were younger at age of diagnosis, had early stage of cancer and good survival.
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characteristics as well as the survival outcome of women di-
agnosed with synchronous endometrial cancer and epithelial 
ovarian cancer in Singapore. The focus will be on endometri-
oid type for uterine cancers.
MATERIALS AND METHODS
This was a retrospective cohort study conducted in KK 
Women’s and Children’s Hospital, a large tertiary institution in 
Singapore. The sample consisted of women with synchronous 
primary endometrial cancer and epithelial ovarian cancers 
who sought care from the institution, and who were followed 
up over a period of 10 years from 2000 to 2009. The medical 
information required was retrieved from the KK Gynaecologi-
cal Cancer Centre Database as well as the patient records. 
The clinico-pathological factors analyzed include the age at 
diagnosis, presenting symptoms, histology types and stage 
of disease. The stage of the endometrial and ovarian cancer 
was based on the FIGO 1988 classification. In our centre, the 
new FIGO staging (2009) classification was adopted from 2010 
onwards hence was not used in this retrospective study. All 
patients underwent a total hysterectomy, bilateral salpingo-
oophorectomy, bilateral pelvic lymphadenectomy and 
omentectomy. Patients with advanced ovarian cancer were 
debulked to residual disease less than 1 cm in our centre. All 
surgical specimens were examined by a pathologist at our 
institution, according to the criteria described by Scully et al. 
[4] The pathological criteria for synchronous primary cancers 
of the endometrium and ovary were as follows: 1) histological 
dissimilarity of tumors; 2) no or only superficial myometrial 
invasion of endometrial tumor; 3) no vascular space invasion 
of endometrial tumor; 4) atypical endometrial hyperplasia 
additionally present; 5) absence of other evidence of spread 
of endometrial tumor; 6) ovarian tumor unilateral (80-90% of 
cases); 7) ovarian tumors located mainly in parenchyma; 8) 
no vascular space invasion, surface implants, or predominant 
hilar location in ovary; 9) absence of other evidence of spread 
of ovarian tumor; and 10) ovary endometriosis present. Pa-
tients with non-endometrioid adenocarcinoma of the uterus, 
borderline and non-epithelial ovarian tumors such as germ 
cell or sex cord stromal tumors were excluded from this study. 
Adjuvant treatment such as chemotherapy was given to pa-
tients with high risk features or advanced disease. All patients 
were followed up routinely with physical examination and 
biochemical markers such as CA-125. 
Data analysis was performed using Stata ver. 11.1 (Stata Co., 
College Station, TX, USA), and survival analysis for follow-up 
data was adopted and poisson regression was used to derive 
hazard ratios.
RESULTS
A total of 75 patients with synchronous cancers were identi-
fied of which 46 patients met the inclusion criteria. There were 
4 patients lost to follow-up. The median follow-up period 
for the 46 patients was 74.06 months (range, 23.34 to 134.71 
months). The incidence rate for synchronous endometrial 
and ovarian cancer was 8.7% of all epithelial ovarian cancers 
and 4.9% of all endometrial cancers diagnosed over this time 
frame. 
The median age at diagnosis was 47.3 years ranging from 
35.7 to 83.2 years. The cohort consisted of 41 ethnic Chinese 
(89.1%), 4 Malays (8.7%), and 1 Filipino (2.2%). The most com-
mon presenting symptom was abnormal uterine bleeding 
Table 2. Characteristics of the endometrial tumors (n=46)
Characteristics Frequency (%)
Stage
IA  17 (37)
IB  15 (32.6)
IC 2 (4.3)
IIA  2 (4.3)
IIB  2 (4.3)
IIIA  4 (8.7)
IIIC 4 (8.7)
Grade
1 32 (69.6)
2 12 (26.1)
3 2 (4.3)
Myoinvasion
Absent  22 (47.8)
<50% invasion  18 (39.1)
>50% invasion  6 (13.0)
Lymphovascular space invasion
Absent  32 (69.6)
Present  14 (30.4)
Table 1. Presenting symptoms (n=46)
Presenting symptoms  No. (%)
Abnormal bleeding  17 (36.9)
Abdominal/pelvic mass  13 (28.3)
Abdominal distension  9 (19.6)
Abdominal/pelvic pain  8 (17.4)
Others 6 (13.0)Synchronous cancers of the endometrium and ovary
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(e.g., postmenopausal bleeding or irregular menses) and they 
were found in 17 patients (36.9%). Thirteen patients (28.3%) 
presented with an abdominal pelvic mass instead. Endome-
triosis was found in 27 patients (58.7%). The other characteris-
tics are listed in Table 1. Thirty seven patients (80.4%) received 
adjuvant platinum based chemotherapy and 6 patients (13%) 
received adjuvant radiotherapy post surgery. Two patients re-
ceived both adjuvant chemotherapy and radiotherapy.
The histopathological characteristics of the endometrial 
cancers are listed in Table 2. We found that 69.6% of patients 
had grade 1 tumors and 73.9% had FIGO stage I cancer. There 
was no stage IV endometrial cancer. Myometrial invasion was 
seen in 52.1% of patients and lymph-vascular space invasion 
in 30.4% of patients. 
The histopathological characteristics of the ovarian cancers 
are listed in Table 3. We found that 58.7% of patients had FIGO 
stage I cancers and 47.8% had grade 1 tumors. There was no 
stage IV ovarian cancer. Endometrioid histology accounted for 
73.9% of all cases and the remaining histology types include 
serous, mucinous, clear cell, undifferentiated and adenosqua-
mous carcinoma. 
There were 5 (10.9%) deaths, therefore the crude mortality 
rate was at 11. 14 (95% confidence interval [CI], 4.64 to 26.76) 
per 10
3 person months. There were 6 (13.6%) cases of recur-
rence and the cumulative survival was 84% (95% CI, 70.87 to 
97.13). 
The difference in mortality rate by age of 50 years was 3.04 
(95% CI, 0.27 to 3.23) per 10
3 person months (p=0.027); by his-
tology, difference in mortality rate was 1.06 (95% CI, -1.92 to 
4.03) per 10
3 person months (p=0.255).
Further analysis of the following risk factors (Table 4), we 
Table 3. Characteristics of the epithelial ovarian tumors (n=46)
Characteristics Frequency (%)
Stage
IA  5 (10.9)
IB 4 (8.7)
IC 18 (39.1)
IIA 1 (2.2)
IIB  1 (2.2)
IIC 8 (17.4)
IIIA 1 (2.2)
IIIB 1 (2.2)
IIIC  7 (15.2)
Grade
1  22 (47.8)
2  18 (39.1)
3  6 (13.0)
Histology
Endometrioid  34 (73.9)
Non-endometrioid  12 (26.1)
Lymphovascular space invasion
Absent  40 (87.0)
Present  6 (13.0)
Surface involvement
Absent  22 (47.8)
Present  24 (52.2)
Bilaterality
Absent  33 (71.7)
Present  13 (28.3)
Table 4. Hazard ratios for age, grade, histology, and staging (n=46)
Variable Category Frequency
no (%)
Deaths
no (%)
Mortality rate
(per 10
3 person mo)
rate (95% CI)
Hazard ratio 
(95% CI)
p-value
(Wald’s test)
Age (yr) ≤50 30 (65.2) 1 (3.3) 0.45 (0.06-3.23) Reference 0.072
>50 16 (34.8) 4 (25.0) 3.49 (1.31-9.30) 7.5 (0.84 -67.10)
Stage 1/1 20 (43.5) 0 (0) - * -
Others 26 (56.5) 5 (19.2) 2.02 (0.84-4.86)
Grade Grade 1/1 13 (28.3) 0 (0) - * -
Others 33 (71.7) 5 (15.2) 2.77 (1.15-6.66)
Histology Endometrioid/endometrioid 34 (73.9) 3 (8.8) 1.22 (0.39-3.77) Reference 0.486
Endometrioid/others 12 (26.1) 2 (16.7) 2.28 (0.57-9.11) 1.89 (0.32-11.30)
Endometriosis No 27 (58.7) 3 (11.1) 1.37 (0.44-4.26) 0.94 (0.16-5.67) 0.953
Yes 19 (41.3) 2 (10.53) 1.72 (0.43-6.88)
CI, confidence interval.
*No Hazard ratio calculated due to no deaths observed in the category shown.Yong Kuei Lim, et al.
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found that the age >50 years has a hazard ratio of 7.5 (95% CI, 
1.21 to 97.19) with a borderline p-value 0.072. Those with dis-
similar (endometrioid/non-endometrioid) histology types also 
appear to have a higher risk of dying (hazard ratio, 1.89) com-
pared to the endometrioid/endometrioid histology group 
though this did not reach statistical significance (p=0.486). 
There were no deaths in those with concurrent histological 
grade 1 ovarian and endometrial tumors or those with con-
current stage I ovarian and endometrial cancers. There were 
14 patients with at least one stage III synchronous cancer and 
there were 5 deaths (35.7%) observed in this group with ad-
vanced disease.
DISCUSSION
Synchronous primary cancer of the uterus and ovary is an 
uncommon event and this occurs in about 4.9% of all endo-
metrial cancers and 8.7% of all ovarian cancers in our institu-
tion. This is similar to that reported by other authors [1,5,6]. 
On the other hand, ovarian metastases have been reported to 
occur in about 5% of primary uterine cancers [7], hence it is 
important to differentiate between the two since it will affect 
the subsequent treatment as well as the prognosis of affected 
women. In order to differentiate between the two groups, 
pathologists have proposed a set of histological criteria to aid 
in the evaluation of these tumors [4,8]. Methods of molecular 
analysis such as DNA flow cytometry, loss of heterozygosity 
on chromosome, X chromosome inactivation, PTEN/MMAC1, 
beta-catenin, and microsatellite instability have also been de-
veloped to help in the differentiation but, to date there is no 
absolute consensus as to which method is the best [9-14]. 
Women with synchronous endometrial and ovarian cancer 
tend to be 10 to 20 years younger than women who suffer 
from ovarian or uterine cancer alone (predominantly post-
menopausal) and the median age reported by various authors 
range from 41 to 54 years. In our cohort, the median age at 
diagnosis was 47.3 years. The younger age at diagnosis and 
multiple site of cancer also brings to question whether there 
is a possibility of familial cancer syndrome such as Lynch syn-
drome (hereditary non-polyposis colorectal cancer, HNPCC). 
However 2 studies have shown that the prevalence of HNPCC 
accounts for only 3% and 7% of cases [5,15]. The pathogenesis 
for synchronous uterine/ovarian cancer is presently unclear. 
Some authors have suggested that the epithelia of the cervix, 
uterus, fallopian tubes, ovaries and peritoneal surface share 
molecular receptors (so called secondary Mullerian system) 
responding to carcinogenic stimulus leading to the develop-
ment of synchronous primary tumors [16]. However, this can 
only explain synchronous tumors of similar histology and not 
dissimilar types.
Several studies have shown that patients with synchronous 
primary cancers have a good overall prognosis [1,5,6,17,18]. 
For instance, the Gynecologic Oncology Group (GOG) study 
found that women with synchronous primary endometrial 
and ovarian cancers had an overall prognosis of 86% 5 year 
survival and 80% 10 year survival [1]. The prognosis for our 
series of patients with synchronous endometrial and ovarian 
cancers appears to be good as well with a cumulative overall 
survival of 84% (Fig. 1) 
In the analysis of risk factors, we found that age to be an 
important factor. Those diagnosed below the age of 50 years 
had a better prognosis than those above 50 years (p=0.027). 
Similarly, Caldarella et al. [6] also showed that age is an im-
portant prognostic factor; the 5 year survival was 94.1% (<50 
years) compared to 53.7% (>50 years) (p=0.004).
In our cohort, there was a trend towards better survival for 
patients with endometrioid/endometrioid tumors versus 
those with endometrioid/other tumors though it did not 
reach statistical significance (p=0.255). Similarly, Soliman et al. 
[5] reported that patients with endometrioid/endometrioid 
tumors of the uterus and ovary had a better overall survival. 
Eifel et al. [17] has also reported that patients with endome-
trioid/endometrioid synchronous tumors had a better overall 
prognosis when compared to patients with stage II ovarian 
cancers or stage III endometrial cancers. On the other hand, 
Caldarella et al. [6] reported that there was no relevant differ-
ence survival in their study. Zaino et al. [1] reported that early 
stage and low histological grade especially in subtype of en-
dometrioid/endometrioid histology have a favorable overall 
prognosis. 
Chiang et al. [18] showed that early stage of synchronous 
cancer had a more significant influence on survival than his-
Fig. 1. Kaplan-Meier survival analysis (n=46). CI, confidence interval.Synchronous cancers of the endometrium and ovary
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tology type though they also reported that patients with con-
cordant endometrioid endometrial and ovarian tumors had 
a good survival potential and prognosis. In our study, there 
were no deaths in patients with concordant stage I as well as 
concordant grade 1 endometrial and ovarian cancers. On the 
other hand, in patients with at least one stage III synchronous 
cancer, the proportion of patients who survived was 64.3% 
(9/14). Though endometriosis was seen in 58.7% of our cases, 
it was not found to be associated with an increased risk of 
mortality (p=0.953).
Compared to other papers, the focus of our study was to 
look at patients with purely endometrioid adenocarcinoma 
of the uterus and epithelial ovarian cancer. The main limita-
tion of our study is that it is a retrospective study with limited 
numbers as a result of excluding non endometrioid types of 
endometrial uterine cancers. However, due to the rarity of 
this type of condition and the fact that diagnosis is usually 
made after primary surgery, it is difficult to recruit patients in 
a prospective study. Nevertheless, our study does show that 
women with synchronous primary endometrial and ovarian 
cancer were younger at age of diagnosis, with the majority 
presenting with early stage disease and good overall survival. 
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